CDEK
← All drugs Report issue

terbinafine

Trade name: lamisil

Small moleculeapproved

Approved

Dec 30, 1992

Terbinafine (brand name Lamisil, Terbisil, Terboderm and others) is an antifungal medication used to treat ringworm and fungal nail infections. Terbinafine inhibits ergosterol synthesis by inhibiting squalene epoxidase, an enzyme that is part of the fungal cell membrane synthesis pathway. Because terbinafine prevents the conversion of squalene to lanosterol, ergosterol cannot be synthesized. This is thought to change cell membrane permeability, causing fungal cell lysis. Many side effects and adverse drug reactions have been reported with oral terbinafine hydrochloride possibly due to its extensive biodistribution and the often extended durations involved in antifungal treatment (longer than two months). — NCATS

Clinical trial activity

56 trials · 47 clinical orgs · 23 marketing orgs

Phase 1
16
Phase 2
32
Phase 3
17
Phase 4
1

Earliest trial started Nov 2, 1999 (NCT00002394)

Timeline

1990s

  1. Dec 30, 1992

    Novartis — Earliest FDA Approval

  2. Dec 30, 1992

    Novartis — NDA Secondary Org

  3. Dec 30, 1992

    Novartis — NDA Organization

  4. Mar 9, 1999

    GlaxoSmithKline — NDA Secondary Org

2000s

  1. Jan 1, 2002

    Teva — Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2004

    Novartis — Earliest Phase 3 Sponsor(trial)

  3. May 19, 2004

    Andrx — Marketing Organization

  4. Jan 1, 2005

    Earliest Phase 2 Sponsor(trial)

  5. Mar 11, 2005

    Gedeon Richter Ltd. — Marketing Organization

  6. Jun 27, 2005

    Roxane Laboratories — Marketing Organization

  7. Jun 27, 2005

    Boehringer Ingelheim — Marketing Organization

  8. Dec 13, 2005

    Mylan — Marketing Organization

  9. Jul 2, 2007

    Apotex — Marketing Organization

  10. Jul 2, 2007

    Aurobindo Pharma — Marketing Organization

  11. Jul 2, 2007

    Cipla — Marketing Organization

  12. Jul 2, 2007

    Dr. Reddy's Laboratories — Marketing Organization

  13. Jul 2, 2007

    Glenmark Pharmaceuticals — Marketing Organization

  14. Jul 2, 2007

    Harris Laboratories, Incorporated — Marketing Organization

  15. Jul 2, 2007

    Invagen Pharms — Marketing Organization

  16. Jul 2, 2007

    Orchid Pharma — Marketing Organization

  17. Jul 2, 2007

    Taro Pharmaceuticals — Marketing Organization

  18. Jul 2, 2007

    Teva — Marketing Organization

  19. Jul 2, 2007

    Wockhardt — Marketing Organization

  20. Jul 2, 2007

    Emed Medcl — Marketing Organization

  21. Jul 2, 2007

    Orbion Pharms — Marketing Organization

  22. Jul 2, 2007

    Heritage Pharma — Marketing Organization

  23. Jul 2, 2007

    Chartwell Pharmaceuticals — Marketing Organization

2010s

  1. Jun 4, 2010

    Esteve Labs — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedDec 30, 1992

Chemistry & pharmacology

Loading structure…

SMILES

CN(C/C=C/C#CC(C)(C)C)Cc1cccc2ccccc12
Mol. weight
291.44 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral, Topical
Availability
Over the Counter

Oral

Yes

Parenteral

No

Topical

Yes

Sources

Also known as

  • athlete's foot
  • da 5505
  • (e)-n-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-1-naphthalene methanamine
  • (e)-n-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-1-naphthalene methanamine
  • (e)-n-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-1-naphthalenemethylamine
  • (e)-n-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-1-naphthalenemethylamine
  • (e)-n-(6,6-dimethyl-2-heptenynyl)-n-methyl-1-naphthalenementhamin hydrochloride
  • lamisil
  • lamisil
  • lamisil
  • lamisil
  • lamisil
  • lamisil at
  • lamisil at
  • lamisil once
  • mob015
  • p-3058
  • sf 86-327
  • sf-86327
  • sf-86327
  • sf-86-327
  • sf-86-327
  • sf-86-327
  • tdt067
  • tdt-067
  • terbinafina
  • terbinafina
  • terbinafine
  • terbinafine
  • terbinafine
  • terbinafine
  • terbinafine
  • terbinafine
  • terbinafine
  • terbinafine
  • terbinafine
  • terbinafine
  • terbinafine
  • terbinafine hcl
  • terbinafine hcl
  • terbinafine hcl
  • terbinafine hydrochloride
  • terbinafine hydrochloride
  • terbinafine hydrochloride
  • terbinafine hydrochloride
  • terbinafine hydrochloride
  • terbinafine hydrochloride
  • terbinafine, (z)-isomer
  • terbinafinum
  • terbinafinum
  • terbinol

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07242703N/ADec 1, 2025Cairo University
NCT07152327N/AOct 1, 2025Assiut University
NCT07068256N/AApr 1, 2025RESnTEC, Institute of Research
NCT06400056Phase 1May 31, 2024Assiut University
NCT05881980Phase 2/Phase 3 (Phase 3)May 31, 2023Dhaka Medical College
NCT05279846Phase 3May 9, 2022Moberg Pharma AB
NCT06295328Phase 1/Phase 2 (Phase 2)Apr 13, 2022University of Amsterdam
NCT05578950Phase 1Mar 1, 2022Government of Pakistan
NCT05049525Phase 2Jan 31, 2022University of Montreal
NCT05135910Phase 2Dec 1, 2021Hallux, Inc., OrthoArizona, East Valley Foot & Ankle Specialists
NCT05128916Phase 3Dec 1, 2021Sohag University
NCT05119712Early Phase 1 (Phase 1)Mar 9, 2021Oregon Health and Science University, The Malassezia Foundation
NCT04880980Phase 3Mar 1, 2021Government of Pakistan
NCT04188574Phase 2Jan 31, 2020Blueberry Therapeutics, IQVIA
NCT03999437Phase 2Jan 2, 2019United Laboratories Inc
NCT02019446N/AJul 1, 2018BCDiabetes.Ca, BritaMed, Inc., University of British Columbia
NCT03471455Phase 2Apr 30, 2018Postgraduate Institute of Medical Education and Research
NCT03244280Phase 1Dec 16, 2017Moberg Pharma AB
NCT06369675Phase 1Oct 19, 2017Moberg Pharma AB, TKL Research
NCT06369727Phase 1Oct 15, 2017Moberg Pharma AB
Showing 20 of 56 trials
Page 1 / 3

Organizations

Research & Development (47)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Moberg Pharma ABFor profit8832010
NovartisFor profit7721999
PRACSFor profit4022004
Assiut UniversityAcademic/Hospital3332017
Polichem S.A.For profit3312014
Celtic Pharma Development ServicesFor profit2222009
Dr. Reddy's LaboratoriesFor profit2212002
Government of PakistanGovernment2222021
MylanFor profit2212004
Nitric BioTherapeutics, IncFor profit2212010
Novum Pharmaceutical Research ServicesFor profit2012002
PPDFor profit2022009
Roxane LaboratoriesFor profit2212004
SFBC AnapharmFor profit2012002
TevaFor profit2212002
AlmirallFor profit1012017
Apricus BiosciencesFor profit1112005
BayerFor profit1112009
BCDiabetes.CaAcademic/Hospital1112018
Blueberry TherapeuticsFor profit1112020
47 organizations
Page 1 / 3

Marketing (26)

OrganizationOrg typeRelationshipDate
AndrxFor profitMKTGMay 19, 2004
ApotexFor profitMKTGJul 2, 2007
Aurobindo PharmaFor profitMKTGJul 2, 2007
Boehringer IngelheimFor profitMKTGJun 27, 2005
Chartwell PharmaceuticalsFor profitMKTGJul 2, 2007
CiplaFor profitMKTGJul 2, 2007
Dr. Reddy's LaboratoriesFor profitMKTGJul 2, 2007
Emed MedclFor profitMKTGJul 2, 2007
Esteve LabsFor profitMKTGJun 4, 2010
Gedeon Richter Ltd.For profitMKTGMar 11, 2005
GlaxoSmithKlineFor profitNDA2Mar 9, 1999
GlaxoSmithKlineFor profitSYNOct 17, 1997
Glenmark PharmaceuticalsFor profitMKTGJul 2, 2007
Harris Laboratories, IncorporatedFor profitMKTGJul 2, 2007
Heritage PharmaFor profitSYNJul 2, 2007
Heritage PharmaFor profitMKTGJul 2, 2007
Invagen PharmsFor profitMKTGJul 2, 2007
MylanFor profitMKTGDec 13, 2005
NovartisFor profitNDA2Dec 30, 1992
NovartisFor profitNDADec 30, 1992
Orbion PharmsFor profitMKTGJul 2, 2007
Orchid PharmaFor profitMKTGJul 2, 2007
Roxane LaboratoriesFor profitMKTGJun 27, 2005
Taro PharmaceuticalsFor profitMKTGJul 2, 2007
TevaFor profitMKTGJul 2, 2007
WockhardtFor profitMKTGJul 2, 2007